Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research Group
- Conditions
- Advanced stage Hodgkin Lymphoma10025319
- Registration Number
- NL-OMON39829
- Lead Sponsor
- European Organisation for Research in Treatment of Cancer (EORTC)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 190
* Previously untreated, histologically proven classical Hodgkin lymphoma
* Clinical stages III/IV (Ann Arbor, see Appendix F)
* Age 18-60
* WHO performance 0-2 (see Appendix C)
* FDG-PET/CT scan prospectively planned after one cycle of chemotherapy in all patients
* Adequate organ function:;* Heart:
New York Heart Association (NYHA) functional classification <= II (EF >= 50% or FS >= 25%)
No symptomatic coronary heart disease (stable angina pectoris is allowed),
No severe uncontrolled hypertension.;* Liver: Total Bilirubin <= 2 x UNL, alanine aminotransferase (ALT, SGPT) <= 3 x UNL, aspartate aminotransferase (AST, SGOT) <= 3 x UNL (exception: elevated values due to HL liver involvement).;* Kidney: creatinine clearance >= 60 ml/min (measured or calculated according to the method of Cockcroft), uric acid, calcium (all <UNL).;* Hematological: Hemoglobin >= 10 g/dl, Leukocyte concentration >= 3.0 x 109/L absolute neutrophil count >= 1.5 x 109/L, platelets >= 75 x 109 /L. (exception: reduced values related to HL (e.g. BM infiltration, splenomegaly));Patients with a buffer range from the normal values of +/- 10% for hematology and +/- 10% for biochemistry are acceptable.;* Patients of childbearing/reproductive potential should use adequate birth control measures during the whole duration of study treatment.;* Female subjects of childbearing potential (defined as any female subject unless she meets at least one of the following criteria: Age >=50 years and naturally amenorrheic for >= 1 year {amenorrhea following cancer therapy does not rule out childbearing potential}, premature ovarian failure confirmed by a specialist gynecologist, previous bilateral salpingo-oophorectomy or hysterectomy, XY genotype, Turner syndrome or uterine agenesis.) must:;* Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/ml not more than 3 days before the start of study medication. This requirement also applies to women of childbearing potential who practice complete and continued abstinence;* Male subjects must:;* Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study therapy if their partner is of childbearing potential and has no contraception.;* Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.;* Written informed consent according to ICH/EU Good Clinical Practice, and national/local regulations
No pregnancy or breast feeding
* No specific contraindications to BEACOPPesc therapy, so therefore:
* poorly controlled diabetes mellitus
* known HIV infection
* chronic active hepatitis B and/or hepatitis C
* concomitant or previous malignancies with the exception of basal cell skin tumors, adequately treated carcinoma in situ of the cervix and any cancer that has been in complete remission for > 5 years
* No psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Freedom from treatment failure (FFTF) </p><br>
- Secondary Outcome Measures
Name Time Method <p>* Response at the end of therapy (chemotherapy and radiotherapy, whenever<br /><br>applicable);<br /><br>* Progression-free survival (PFS) ;<br /><br>* Overall survival ;<br /><br>* Serum TARC levels at baseline, during treatment and follow up;<br /><br>* Frequency of acute toxicity and long-term toxicity in terms of second<br /><br>malignancies, cardiovascular and pulmonary events.</p><br>